Zum Inhalt

HealthOSArzneimittel

Arbeitsbereiche

Nachschlagen

Wirkstoffe & Arzneimittelsicherheit

Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (1)

Wechselwirkungen · Lojuxta

Lojuxta 2 mg hard capsules Lojuxta 5 mg hard capsules Lojuxta 10 mg hard capsules Lojuxta 20 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11

HOS-127355 · Präparat HOS-096397

Weak CYP3A4 inhibitors are When administered with atorvastatin, the expected to increase the exposure of dose of lomitapide should either be taken lomitapide when taken 12 hours apart or be decreased by half (see simultaneously. section 4.2). The dose of lomitapide should be taken 12 hours apart from any other When lomitapide 20 mg was concomitant weak CYP3A4 inhibitors. co-administered simultaneously with Examples of weak CYP3A4 inhibitors atorvastatin, a weak CYP3A4 include: alprazolam, amiodarone, inhibitor, lomitapide AUC and Cmax amlodipine, atorvastatin, azithromycin, increased approximately 2-fold. bicalutamide, cilostazol, cimetidine, When the dose of lomitapide was ciclosporin, clotrimazole, fluoxetine, taken 12 hours apart from fluvoxamine, fosaprepitant, ginkgo, atorvastatin, no clinically meaningful goldenseal, isoniazid, ivacaftor, lacidipine, increase in lomitapide exposure was lapatinib, linagliptin, nilotinib, observed. oestrogen-containing oral contraceptives, pazopanib, peppermint oil, propiverine, When lomitapide 20 mg was co- ranitidine, ranolazine, roxithromycin, Seville administered simultaneously or oranges, tacrolimus, ticagrelor and tolvaptan. 12 hours apart with ethinyl This list is not intended to be comprehensive estradiol/norgestimate, a weak and prescribers should check the prescribing CYP3A4 inhibitor, no clinically information of medicinal products to be co- meaningful increase in lomitapide administered with Lojuxta for potential exposure was observed. CYP3A4 mediated interactions.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) lacidipine (HOS-113865) norgestimate (HOS-110544) cilostazol (HOS-111550) cimetidine (HOS-085835) atorvastatin (HOS-086304) alprazolam (HOS-086171) roxithromycin (HOS-127365) propiverine (HOS-127363) peppermint oil (HOS-127362) estradiol (HOS-090751) amlodipine (HOS-086287) azithromycin (HOS-088112) clotrimazole (HOS-090574) bicalutamide (HOS-127356) tolvaptan (HOS-109429) fosaprepitant (HOS-117427) lapatinib (HOS-122565) ivacaftor (HOS-109475) tacrolimus (HOS-085202) linagliptin (HOS-124309) pazopanib (HOS-122551) fluoxetine (HOS-085946) ranitidine (HOS-085660) amiodarone (HOS-085596) fluvoxamine (HOS-085908) ranolazine (HOS-086141) isoniazid (HOS-088590) nilotinib (HOS-086218)

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2026-06-25T14:24:00Z · SHA-256 56c36935b5cda4380e359902f1acbc5ec5bb081beeb96ca75e5ad86521fcd98c · Passage 714d59bc1bbe3ac0c5d4eeaa178f455a97b56caa11d4ced4ec39de50572ee7d0 · Zeichen 2870–5037 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.